Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Victor Priego"'
Autor:
Guillermo Garcia-Manero, Kimo Bachishvili, Elizabeth A. Griffiths, Amer M. Zeidan, Elie Traer, Lalit Saini, Harshad Amin, Sanjay Mohan, Michael Lübbert, Lori Maness-Harris, James M Foran, Dominik Selleslag, Blanca Xicoy Cirici, Daniel Aaron Pollyea, David Sallman, Aref Al-Kali, Jesus Berdeja, Haifa Kathrin Al-Ali, Nancy Y Zhu, Patricia Font Lopez, Guillermo Sanz Santillana, Valeria Santini, Habte A. Yimer, Larry D Cripe, Victor Priego, Olatoyosi Odenike, Bert Heyrman, David Valcarcel, Pankit Vachhani, Yuri Sano, Beloo Mirakhur, Aram Oganesian, Harold Keer, Abdulraheem Yacoub
Publikováno v:
HemaSphere, Vol 7, p e551265b (2023)
Externí odkaz:
https://doaj.org/article/c645340b1872424db531617d804b3c67
Autor:
Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Publikováno v:
Blood. 140:6498-6500
Autor:
Sanjay Goel, Susanna Varkey Ulahannan, Anthony J. Olszanski, Patricia LoRusso, Rachel E. Sanborn, Sunil Sharma, Leisha A. Emens, Matthew Reilley, Victor Priego, Shuli Li, Bingxia Wang, Lixian Dong, Kris Sachsenmeier, John Gibbs, Robert Gharavi, Alonzo Martinez, Igor Proscurshim, Robert J. Fram, Alejandro Gomez-Pinillos, Drew W. Rasco
Publikováno v:
Journal of Clinical Oncology. 40:2506-2506
2506 Background: SUMOylation is a post-translational modification with a role in limiting type 1 interferon (IFN-1)-dependent immune responses. Subasumstat is a small-molecule inhibitor of SUMOylation with the potential to increase antitumor immunity
Autor:
Jennifer Clauson, Kevin Ritt, Matthew M. Cooney, Amy Franzen, D. Oubre, Megan Shulman, Raju Kumar Vaddepally, Ewelina Protomastro, Kimberly L. Blackwell, Minal A. Barve, Francis Mark Senecal, Angela Saverimuthu, Meghan Degele, Ian Churchill Anderson, Stephanie OLeary, Victor Priego
Publikováno v:
Journal of Clinical Oncology. 39:1563-1563
1563 Background: Clinical trials that require patients to have specific actionable mutations based on next generation sequencing (NGS) present unique problems, such as recruiting patients with rare mutations, low enrollment rates, and distance betwee
Autor:
Jerome Canady, Taisen Zhuang, Giacomo Basadonna, Anu Gupta, Shruti Wigh, Victor Priego, Kimberly Wiley, Emil I. Cohen, Michael Keidar, Barry Trink, Steven Gordon, Tammy Naab, Warren Rowe, Dereck Chiu, Robert L. DeWitty, Sterlyn Jones, Alexey Shashurin
Publikováno v:
Comprehensive Clinical Plasma Medicine ISBN: 9783319676265
The authors report the first clinical experience using CAP for Stage IV metastatic colon cancer. The report describes the patient’s history, chemotherapy, radiation, surgical treatment and ex-vivo and intra-operative treatment of the tumor and norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be663601e56861e8f9330ced95a35308
https://doi.org/10.1007/978-3-319-67627-2_9
https://doi.org/10.1007/978-3-319-67627-2_9
Autor:
Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Amelia Orejudos, Angela Lopez
Publikováno v:
Blood. 124:2775-2775
Background: We describe here plt response and remission observed with romiplostim in patients with ITP for ≤6 months (mos). Methods: Patients with ITP for ≤6 mos who received 1st-line therapies only subsequently received 12 mos of weekly (QW) rom
Autor:
Roberto Stasi, Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Catherine Jia, Angela Lopez
Publikováno v:
Blood. 122:1074-1074
Background We describe here platelet response and remission observed with romiplostim treatment in patients with ITP. Methods Patients with an ITP diagnosis for less than 6 months who received first-line therapies only (ie, corticosteroids, IVIG, ant